Robert Brightharp, MD
Family Medicine · Myrtle Beach, SCNPI 1205197019
Payments from drug & device makers
Across 173 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$696
- AstraZeneca$451
- Amgen$433
- Lilly USA, LLC$365
- AbbVie$340
- Boehringer Ingelheim$131
- plus $900 from 23 others
What the payments were for
- Food & beverage$3,316100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $696 |
| AstraZeneca | 23 | $451 |
| Amgen | 14 | $433 |
| Lilly USA, LLC | 17 | $365 |
| AbbVie | 18 | $340 |
| Boehringer Ingelheim | 8 | $131 |
| Pfizer | 7 | $113 |
| Abbott | 6 | $94 |
| GSK | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $72 |
| Exact Sciences | 4 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Novartis | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 4 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Merck | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Seqirus USA Inc | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Bayer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Sonex Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,316 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 79 | $61,235 |
| RybelsusSemaglutide | 37 | $34,949 |
| MounjaroTirzepatide | 29 | $30,146 |
| EliquisApixaban | 24 | $23,945 |
| OzempicSemaglutide | 17 | $23,070 |
| JanuviaSitagliptin Phosphate | 18 | $19,018 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,917 |
| MyrbetriqMirabegron | 14 | $7,040 |
| Lagevrio (Eua)Molnupiravir | 12 | $5,733 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,675 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,518 |
| Fentanyl | 11 | $2,136 |
| Pravastatin Sodium | 147 | $1,550 |
| Atorvastatin Calcium | 174 | $1,481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $131 | $61,23579 claims |
| Novo NordiskRybelsus, Ozempic | $696 | $58,01954 claims |
| Lilly USA, LLCMounjaro | $365 | $30,14629 claims |
| MerckJanuvia, Lagevrio (Eua) | $34 | $24,75230 claims |
| PfizerEliquis | $113 | $23,94524 claims |
| GSKTrelegy Ellipta | $75 | $13,91718 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $7,04014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Myrtle Beach
- Chad HubertyMyrtle Beach$575K
- Jonathan BornfreundMyrtle Beach$222K
- David WeitzmanMyrtle Beach$181K
- Patrick RyanMyrtle Beach$167K
- Edward McCarthyMyrtle Beach$86K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.